Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19
13 Dec 2025
Treatment with nirmatrelvir/ritonavir (NMV/r) provides good value for money because of its health benefits for patients with mild-to-moderate COVID-19 who are at an increased risk of progressing to severe disease, according to the results of a systematic literature review of economic value.
Resources
Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19
Nirmatrelvir/ritonavir cost-effective for mild-to-moderate COVID-19